Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 23,569Xls
2D Structure
Also known as: 1620458-09-4, Azd0914, Azd-0914, Zoliflodacin [usan], Etx0914, Etx-0914
Molecular Formula
C22H22FN5O7
Molecular Weight
487.4  g/mol
InChI Key
ZSWMIFNWDQEXDT-ZESJGQACSA-N
FDA UNII
FWL2263R77

Zoliflodacin has been used in trials studying the basic science and treatment of Gonorrhoea.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(4'R,6'S,7'S)-17'-fluoro-4',6'-dimethyl-13'-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]spiro[1,3-diazinane-5,8'-5,15-dioxa-2,14-diazatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),10,12(16),13-tetraene]-2,4,6-trione
2.1.2 InChI
InChI=1S/C22H22FN5O7/c1-8-7-33-21(32)28(8)17-12-4-11-5-22(18(29)24-20(31)25-19(22)30)16-10(3)34-9(2)6-27(16)14(11)13(23)15(12)35-26-17/h4,8-10,16H,5-7H2,1-3H3,(H2,24,25,29,30,31)/t8-,9+,10-,16+/m0/s1
2.1.3 InChI Key
ZSWMIFNWDQEXDT-ZESJGQACSA-N
2.1.4 Canonical SMILES
CC1CN2C(C(O1)C)C3(CC4=CC5=C(C(=C42)F)ON=C5N6C(COC6=O)C)C(=O)NC(=O)NC3=O
2.1.5 Isomeric SMILES
C[C@@H]1CN2[C@H]([C@@H](O1)C)C3(CC4=CC5=C(C(=C42)F)ON=C5N6[C@H](COC6=O)C)C(=O)NC(=O)NC3=O
2.2 Other Identifiers
2.2.1 UNII
FWL2263R77
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (2r,4s,4as)-11-fluoro-2,4-dimethyl-8-((4s)-4-methyl-2-oxo-1,3-oxazolidin-3-yl)-1,2,4,4a-tetrahydro-2'h,6h-spiro((1,2)-oxazolo(4,5-g)(1,4)oxazino(4,3-a)quinoline-5,5'-pyrimidine)-2',4',6'(1'h,3'h)-trione

2. Azd-0914

3. Azd0914

4. Etx-0914

5. Etx0914

2.3.2 Depositor-Supplied Synonyms

1. 1620458-09-4

2. Azd0914

3. Azd-0914

4. Zoliflodacin [usan]

5. Etx0914

6. Etx-0914

7. Fwl2263r77

8. (2r,4s,4as)-11-fluoro-2,4-dimethyl-8-((4s)-4-methyl-2-oxo-1,3-oxazolidin-3-yl)-1,2,4,4a-tetrahydro-2'h,6h-spiro((1,2)-oxazolo(4,5-g)(1,4)oxazino(4,3-a)quinoline-5,5'-pyrimidine)-2',4',6'(1'h,3'h)-trione

9. Unii-fwl2263r77

10. Zoliflodacin(azd0914)

11. Zoliflodacin (usan/inn)

12. Zoliflodacin [inn]

13. Zoliflodacin [who-dd]

14. Azd 0914 - Bio-x

15. Chembl3544978

16. Schembl15879500

17. Gtpl10875

18. Azd0914etx0914

19. Ext0914

20. Bdbm139376

21. Dtxsid101028418

22. Azd 0914

23. Ex-a2620

24. Ext-0914

25. Etx0914; Azd0914; Zoliflodacin

26. Db12817

27. Ac-35757

28. Ba164192

29. Hy-17647

30. Cs-0016917

31. D11726

32. Us8889671, 5

33. Q27278240

34. (2r,4s,4as)-11-fluoro-2,4-dimethyl-8-((s)-4-methyl-2-oxooxazolidin-3-yl)-1,2,4,4a-tetrahydro-2'h,6h-spiro[isoxazolo[4,5-g][1,4]oxazino[4,3-a]quinoline-5,5'-pyrimidine]-2',4',6'(1'h,3'h)-trione

35. (2r,4s,4as)-11-fluoro-2,4-dimethyl-8-((s)-4-methyl-2-oxooxazolidin-3-yl)-2,4,4a,6-tetrahydro-1h,1'h-spiro[isoxazolo[4,5-g][1,4]oxazino[4,3-a]quinoline-5,5'-pyrimidine]-2',4',6'(3'h)-trione

36. (4'r,6's,7's)-17'-fluoro-4',6'-dimethyl-13'-[(4s)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]spiro[1,3-diazinane-5,8'-5,15-dioxa-2,14-diazatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),10,12(16),13-tetraene]-2,4,6-trione

37. (7s,11r,13s)-3-((4s)-2-oxo-4-methyltetrahydrooxazole-3-yl)-9-fluoro-11,13-dimethyl-8,7-(ethanoxymethano)-7,8,1',2',3',4'-hexahydrospiro[isoxazolo[4,5-g]quinoline-6(5h),5'(6'h)-pyrimidine]-2',4',6'-trione

38. Spiro(isoxazolo(4,5-g)(1,4)oxazino(4,3-a)quinoline-5(6h),5'(2'h)-pyrimidine)-2',4',6'(1'h,3'h)-trione, 11-fluoro-1,2,4,4a-tetrahydro-2,4-dimethyl-8-((4s)-4-methyl-2-oxo-3-oxazolidinyl)-, (2r,4s,4as)-

2.4 Create Date
2014-08-04
3 Chemical and Physical Properties
Molecular Weight 487.4 g/mol
Molecular Formula C22H22FN5O7
XLogP31.3
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count10
Rotatable Bond Count1
Exact Mass487.15032622 g/mol
Monoisotopic Mass487.15032622 g/mol
Topological Polar Surface Area143 Ų
Heavy Atom Count35
Formal Charge0
Complexity962
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of gonococcal infection


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Topoisomerase II Inhibitors

Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)